Vismodegib-associated hepatotoxicity: A potential side effect detected in postmarketing surveillance

Journal of the American Academy of Dermatology

Volumn 71, Issue 2, 2014, Pages 397-398

  Ventarola, Daniel J ^a   Silverstein, David I ^a  

^a STONY BROOK UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; ERLOTINIB; GAMMA GLUTAMYLTRANSFERASE; PARACETAMOL; VISMODEGIB;

ALBUMIN BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ALOPECIA; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BASAL CELL CARCINOMA; BILIRUBIN BLOOD LEVEL; DRUG SURVEILLANCE PROGRAM; DYSGEUSIA; FATIGUE; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; HUMAN; HYPOALBUMINEMIA; LETTER; LIVER TOXICITY; MUSCLE CRAMP; PRIORITY JOURNAL; SIDE EFFECT; TREATMENT DURATION; WEIGHT REDUCTION;

ADULT; ADVERSE DRUG REACTION REPORTING SYSTEMS; AGED; AGED, 80 AND OVER; ANILIDES; ANTINEOPLASTIC AGENTS; DRUG-INDUCED LIVER INJURY; FEMALE; GASTROINTESTINAL DISEASES; HUMANS; MALE; MIDDLE AGED; PYRIDINES; THROMBOSIS; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 84904662805     PISSN: 01909622     EISSN: 10976787     Source Type: Journal    
DOI: 10.1016/j.jaad.2014.04.023     Document Type: Article

References (8)

1. A. Sekulic, M.R. Migden, A.E. Oro, L. Dirix, K.D. Lewis, and J.D. Hainsworth et al. Efficacy and safety of vismodegib in advanced basal-cell carcinoma N Engl J Med 366 2012 2171 2179
2. M.R. Sharma, T.G. Karrison, B. Kell, K. Wu, M. Turcich, and D. Geary et al. Evaluation of food effect on pharmacokinetics of vismodegib in advanced solid tumor patients Clin Cancer Res 19 2013 3059 3067
3. P.M. LoRusso, C.M. Rudin, J.C. Reddy, R. Tibes, G.J. Weiss, and M.J. Borad et al. Phase I trial of hedgehog pathway inhibitor vismodegib (GDC-0449) in patients with refractory, locally advanced or metastatic solid tumors Clin Cancer Res 17 2011 2502 2511
4. P.M. LoRusso, A. Jimeno, G. Dy, A. Adjei, J. Berlin, and L. Leichman et al. Pharmacokinetic dose-scheduling study of hedgehog pathway inhibitor vismodegib (GDC-0449) in patients with locally advanced or metastatic solid tumors Clin Cancer Res 17 2011 5774 5782
5. J. Berlin, J.C. Bendell, L.L. Hart, I. Firdaus, I. Gore, and R.C. Hermann et al. A randomized phase II trial of vismodegib versus placebo with FOLFOX or FOLFIRI and bevacizumab in patients with previously untreated metastatic colorectal cancer Clin Cancer Res 19 2013 258 267
6. D.D. Von Hoff, P.M. LoRusso, C.M. Rudin, J.C. Reddy, R.L. Yauch, and R. Tibes et al. Inhibition of the hedgehog pathway in advanced basal-cell carcinoma N Engl J Med 361 2009 1164 1172
7. A. Gajjar, C.F. Stewart, D.W. Ellison, S. Kaste, L.E. Kun, and R.J. Packer et al. Phase I study of vismodegib in children with recurrent or refractory medulloblastoma: a pediatric brain tumor consortium study Clin Cancer Res 19 2013 6305 6312
8. S.B. Kaye, L. Fehrenbacher, R. Holloway, A. Amit, B. Karlan, and B. Slomovitz et al. A phase II, randomized, placebo-controlled study of vismodegib as maintenance therapy in patients with ovarian cancer in second or third complete remission Clin Cancer Res 18 2012 6509 6518